Barriers to Chimeric Antigen Receptor T-Cell Therapy
Menée aux Etats-Unis, cette étude retrospective identifie les facteurs entravant l'accès aux immunothérapies à base de lymphocytes CAR-T chez des patients atteints d'un cancer
Chimeric antigen receptor T-cell (CAR-T) therapy has transformed the treatment of hematologic malignant neoplasms. However, clinical application of autologous CAR-T therapy can be complex, possibly limiting patient access. Little is known about the proportion of patients referred to CAR-T therapy for different indications who actually receive it, reasons for not receiving it, and disparities in access. We conducted a retrospective study to address this knowledge gap.
JAMA Oncology , résumé, 2025